FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891288072> ?p ?o ?g. }

• W2891288072 endingPage "7033" @default.
• W2891288072 startingPage "7033" @default.
• W2891288072 abstract "7033 Background: Chemoimmunotherapy is an effective frontline therapy for acute lymphoblastic leukemia (ALL). Ofatumumab (O) binds to a proximal small-loop epitope on CD20 and is more potent in vitro than rituximab. Here we report interim results of its combination with hyper-CVAD (HCVAD) in adult patients (pts) with CD20+ ALL. Methods: Since 7/2011, we have enrolled 63 pts with Ph-negative CD20+ ALL (59 newly diagnosed, 4 previously treated). For the intensive phase, pts received 4 cycles (cy) of HCVAD (odd cy 1, 3, 5, 7) alternating with 4 cy of methotrexate-cytarabine (MTX-Ara-C, even cy 2, 4, 6, 8), and ofatumumab during cy 1-4. For maintenance, pts received POMP for ~30 months (mos), and intensification with MTX/PEGylated asparaginase on mos 6 and 18, and O-HCVAD on mos 7 and 19. Intrathecal MTX-Ara-C was used for CNS prophylaxis. Bulky mediastinal disease was irradiated when indicated. Results: Median age was 41 years (range: 18-71) and median WBC count was 4.6 x10 9 /L (range: 0.6-201 x10 9 /L). 22 pts (35%) had diploid cytogenetics and 8/35 pts (23%) had TP53 mutation. CD20 expression was > 20% in 38 pts (60%), 10-20% in 6 pts (10%) and 1-10% in 16 pts (25%). Median follow-up was 20 mos (range: 1-58) and median number of cy was 8 (range: 1-8). 3 pts (5%) were in CR at the time of enrollment. Of 60 pts evaluable for response, 58 pts (97%) achieved CR; 1 pt achieved CRp and 1 pt died during cy 1 from sepsis. Flow cytometric minimal residual disease (MRD) was negative in 57/62 pts (92%) overall, and in 36/57 pts (57%) at CR. Median time to negative MRD was 0.7 mos. Median time to platelet and neutrophil recovery in cy 1 was 21 and 18 days, respectively. The most common grade 3/4 non-hematological toxicities were infections during induction (49%) and consolidation (72%), elevated transaminases (35%), and hyperbilirubinemia (21%). 5 pts (7%) experienced a grade 3/4 transfusion reaction. 8 pts (13%) received stem cell transplantation in CR1. 10 pts (16%) have relapsed (8 morphological, 2 MRD only). Overall survival and 2-year CR duration rates were 80% and 81%, respectively. Survival outcomes were independent of percentage of CD20 expression. Conclusions: O-HCVAD is safe, effective and results in durable responses in pts with CD20+ ALL. Clinical trial information: NCT01363128." @default.
• W2891288072 created "2018-09-27" @default.
• W2891288072 creator A5000750846 @default.
• W2891288072 creator A5004203354 @default.
• W2891288072 creator A5011548707 @default.
• W2891288072 creator A5015101485 @default.
• W2891288072 creator A5020340537 @default.
• W2891288072 creator A5021380291 @default.
• W2891288072 creator A5022647201 @default.
• W2891288072 creator A5029750735 @default.
• W2891288072 creator A5038307470 @default.
• W2891288072 creator A5049173793 @default.
• W2891288072 creator A5049448914 @default.
• W2891288072 creator A5059600583 @default.
• W2891288072 creator A5061026876 @default.
• W2891288072 creator A5066354077 @default.
• W2891288072 creator A5075581944 @default.
• W2891288072 creator A5085521139 @default.
• W2891288072 creator A5090435894 @default.
• W2891288072 creator A5091492845 @default.
• W2891288072 date "2017-05-20" @default.
• W2891288072 modified "2023-10-18" @default.
• W2891288072 title "Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia." @default.
• W2891288072 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.7033" @default.
• W2891288072 hasPublicationYear "2017" @default.
• W2891288072 type Work @default.
• W2891288072 sameAs 2891288072 @default.
• W2891288072 citedByCount "3" @default.
• W2891288072 countsByYear W28912880722017 @default.
• W2891288072 countsByYear W28912880722022 @default.
• W2891288072 crossrefType "journal-article" @default.
• W2891288072 hasAuthorship W2891288072A5000750846 @default.
• W2891288072 hasAuthorship W2891288072A5004203354 @default.
• W2891288072 hasAuthorship W2891288072A5011548707 @default.
• W2891288072 hasAuthorship W2891288072A5015101485 @default.
• W2891288072 hasAuthorship W2891288072A5020340537 @default.
• W2891288072 hasAuthorship W2891288072A5021380291 @default.
• W2891288072 hasAuthorship W2891288072A5022647201 @default.
• W2891288072 hasAuthorship W2891288072A5029750735 @default.
• W2891288072 hasAuthorship W2891288072A5038307470 @default.
• W2891288072 hasAuthorship W2891288072A5049173793 @default.
• W2891288072 hasAuthorship W2891288072A5049448914 @default.
• W2891288072 hasAuthorship W2891288072A5059600583 @default.
• W2891288072 hasAuthorship W2891288072A5061026876 @default.
• W2891288072 hasAuthorship W2891288072A5066354077 @default.
• W2891288072 hasAuthorship W2891288072A5075581944 @default.
• W2891288072 hasAuthorship W2891288072A5085521139 @default.
• W2891288072 hasAuthorship W2891288072A5090435894 @default.
• W2891288072 hasAuthorship W2891288072A5091492845 @default.
• W2891288072 hasConcept C126322002 @default.
• W2891288072 hasConcept C18031839 @default.
• W2891288072 hasConcept C2776694085 @default.
• W2891288072 hasConcept C2777063308 @default.
• W2891288072 hasConcept C2778020697 @default.
• W2891288072 hasConcept C2778041864 @default.
• W2891288072 hasConcept C2778461978 @default.
• W2891288072 hasConcept C2778714382 @default.
• W2891288072 hasConcept C2779338263 @default.
• W2891288072 hasConcept C2780653079 @default.
• W2891288072 hasConcept C2780790343 @default.
• W2891288072 hasConcept C2909962599 @default.
• W2891288072 hasConcept C71924100 @default.
• W2891288072 hasConcept C90924648 @default.
• W2891288072 hasConceptScore W2891288072C126322002 @default.
• W2891288072 hasConceptScore W2891288072C18031839 @default.
• W2891288072 hasConceptScore W2891288072C2776694085 @default.
• W2891288072 hasConceptScore W2891288072C2777063308 @default.
• W2891288072 hasConceptScore W2891288072C2778020697 @default.
• W2891288072 hasConceptScore W2891288072C2778041864 @default.
• W2891288072 hasConceptScore W2891288072C2778461978 @default.
• W2891288072 hasConceptScore W2891288072C2778714382 @default.
• W2891288072 hasConceptScore W2891288072C2779338263 @default.
• W2891288072 hasConceptScore W2891288072C2780653079 @default.
• W2891288072 hasConceptScore W2891288072C2780790343 @default.
• W2891288072 hasConceptScore W2891288072C2909962599 @default.
• W2891288072 hasConceptScore W2891288072C71924100 @default.
• W2891288072 hasConceptScore W2891288072C90924648 @default.
• W2891288072 hasIssue "15_suppl" @default.
• W2891288072 hasLocation W28912880721 @default.
• W2891288072 hasOpenAccess W2891288072 @default.
• W2891288072 hasPrimaryLocation W28912880721 @default.
• W2891288072 hasRelatedWork W1977027915 @default.
• W2891288072 hasRelatedWork W1987160165 @default.
• W2891288072 hasRelatedWork W2026225959 @default.
• W2891288072 hasRelatedWork W2052868810 @default.
• W2891288072 hasRelatedWork W2079089580 @default.
• W2891288072 hasRelatedWork W2097876567 @default.
• W2891288072 hasRelatedWork W2256822827 @default.
• W2891288072 hasRelatedWork W2580497094 @default.
• W2891288072 hasRelatedWork W2606155555 @default.
• W2891288072 hasRelatedWork W3210753191 @default.
• W2891288072 hasVolume "35" @default.
• W2891288072 isParatext "false" @default.
• W2891288072 isRetracted "false" @default.
• W2891288072 magId "2891288072" @default.
• W2891288072 workType "article" @default.